Lakefront Biotherapeutics (GLPGF) Non-Current Deffered Revenue (2016 - 2025)

Lakefront Biotherapeutics (GLPGF) has reported Non-Current Deffered Revenue for 10 consecutive years, with $779.0 million the latest figure, recorded in Q3 2025.

• On a quarterly basis, Non-Current Deffered Revenue fell 20.93% year-over-year to $779.0 million in Q3 2025; TTM through Sep 2025 was $779.0 million, a 20.93% decrease from a year earlier, with the FY2024 full-year figure at $907.9 million, down 21.22% from the prior year.
• Non-Current Deffered Revenue was $779.0 million for Q3 2025 at Lakefront Biotherapeutics, down from $819.3 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $2.6 billion in Q2 2021 and troughed at $779.0 million in Q3 2025.
• A 5-year average of $1.4 billion and a median of $1.2 billion in 2023 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue dropped 3.0% in 2021 and plunged 31.35% in 2024, its largest moves.
• Over 5 years, Non-Current Deffered Revenue stood at $2.2 billion in 2021, then slipped by 25.55% to $1.7 billion in 2022, then sank by 30.42% to $1.2 billion in 2023, then retreated by 22.22% to $896.4 million in 2024, then retreated by 13.1% to $779.0 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $779.0 million (Q3 2025), $819.3 million (Q2 2025), and $821.9 million (Q1 2025), per Business Quant data.